Essilor Stellest glasses: FDA-approved lens aim to slow myopia progression - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA-Approved Essilor Stellest Lenses Designed to Mitigate Myopia Progression

  • By

  • Matthew Perrone

  • December 1, 2025

Share

Objective:

To introduce and explain the new Essilor Stellest lenses approved by the FDA for slowing myopia progression in children.

Key Findings:
  • Children wearing Stellest lenses showed a 50% reduction in eye lengthening after two years.
  • Potential long-term benefits include reduced risk of severe myopia-related complications like cataracts and retinal detachment.
  • The lenses are priced at $450 and may be covered by major U.S. vision insurance providers.
Interpretation:

The Essilor Stellest lenses represent a significant advancement in myopia management, offering a non-invasive option for children.

Limitations:
  • FDA studies were conducted primarily in Asia; further U.S.-based research is needed to confirm efficacy.
  • Some children reported visual disturbances while wearing the lenses.
Conclusion:

Essilor Stellest lenses provide a promising new option for managing myopia in children, with potential to prevent serious eye health issues in the future.

Original Source(s)

Essilor Stellest glasses: FDA-approved lens aim to slow myopia progression

  • by Matthew Perrone

  • December 1, 2025

Related Content

Effective refractive error coverage and vision impairment among schoolchildren in Xinjiang, China

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.

Outdoor artificial nighttime light may raise childhood myopia risk

Higher exposure was associated with new-onset myopia over 3 years, with risk increasing sharply at higher nighttime light levels.